RAFAEL HOLDINGS, INC. Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
RAFAEL HOLDINGS, INC. (RFL) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of -$170 for the 3-month period ending 2024-04-30, per its 10-Q filed 2024-06-14.
Discontinued › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2024-06-14
- RAFAEL HOLDINGS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2024-04-30 was -$170.00.
- RAFAEL HOLDINGS, INC. net income (loss) from continuing operations available to common shareholders, diluted for the quarter ending 2023-04-30 was -$20.00.
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 3 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 9 month |
|---|---|---|
| 2024-04-30 | -$170.00 10-Q · filed 2024-06-14 | -$90.00 10-Q · filed 2024-06-14 |
| 2023-04-30 | -$20.00 10-Q · filed 2024-06-14 | -$1.81K 10-Q · filed 2024-06-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aditxt, Inc. (ADTX) | United States | $0.000B | |
| CDT Equity Inc. (CDT) | United States | $0.000B | -0.01 |
| Protagenic Therapeutics, Inc.\new (PTIX) | United States | $0.001B | |
| Decoy Therapeutics Inc. (DCOY) | United States | $0.002B | -0.27 |
| Nexentis Technologies Inc. (NXTS) | $0.002B | ||
| ORAGENICS INC (OGEN) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B |